SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

14 Nov 2022 Evaluate
The sales for the September 2022 quarter moved down to Rs. 4812.35 millions as compared to Rs. 5749.97 millions during the year-ago period.The Net Loss for the quarter ended September 2022 is Rs. -39.97 millions as compared to Net Profit of Rs. 185.18 millions of corresponding quarter ended September 2021Operating Profit reported a sharp decline to 149.40 millions from 693.74 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 4812.35 5749.97 -16.31 9044.25 10837.87 -16.55 19790.03 18575.66 6.54
Other Income 204.71 224.10 -8.65 279.36 340.96 -18.07 1234.85 889.96 38.75
PBIDT 149.40 693.74 -78.46 -386.27 863.10 -144.75 2001.15 2763.16 -27.58
Interest 346.60 180.03 92.52 606.77 360.94 68.11 742.41 653.39 13.62
PBDT -197.20 513.71 -138.39 -993.04 502.16 -297.75 1258.74 2109.77 -40.34
Depreciation 243.51 270.89 -10.11 486.47 537.25 -9.45 1043.66 993.42 5.06
PBT -440.71 242.82 -281.50 -1479.51 -35.09 4116.33 215.08 1116.35 -80.73
TAX -400.74 57.64 -795.25 -777.00 -7.96 9661.31 -1586.80 333.95 -575.16
Deferred Tax -205.93 57.64 -457.27 -582.19 -7.96 7213.94 -2.09 123.77 -101.69
PAT -39.97 185.18 -121.58 -702.51 -27.13 2489.42 1801.88 782.40 130.30
Equity 902.90 897.77 0.57 902.90 897.77 0.57 897.90 896.80 0.12
PBIDTM(%) 3.10 12.07 -74.27 -4.27 7.96 -153.63 10.11 14.88 -32.02

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×